MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 55, Issue 2, 2010, Pages 248-253

  Phillips, Christine L ^a,b   Gerbing, Robert ^c   Alonzo, Todd ^c   Perentesis, John P ^a,b   Harley, Isaac T W ^a,b   Meshinchi, Soheil ^d   Bhatla, Deepika ^a,b   Radloff, Gretchen ^a,b   Davies, Stella M ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

AML; Children's oncology group; MDM2; SNP 309; Susceptibility

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PROTEIN MDM2; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955109275     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22519     Document Type: Article

References (27)

1. Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41. (Pubitemid 40321798)
2. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006;98:911-919.
3. Turbin DA, Cheang MC, Bajdik CD, et al. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 2006;19:69-74.
4. Arva NC, Gopen TR, Talbott KE, et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005;280:26776-26787.
5. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promotor attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
6. Nayak MS, Yang J-M, Hait WN. Effect of a single nucleotide polymorphism in the Murine Double Minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007;67:5831-5839.
7. Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008;26:2252-2257.
8. Spector LG, Xie Y, Robison LL, et al. Maternal diet and infant leukemia: TheDNAtopoisomerase II inhibitor hypothesis:Areport from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev 2005;14:651-655.
9. Lange BJ, Dinndorf P, Smith FO, et al. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol 2004;22:150-156.
10. Aplenc R, Alonzo TA, Gerbing RB, et al. Ethnicity and survival in childhood acute myeloid leukemia: A report from the Children's Oncology Group. Blood 2006;108:74-80.
11. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG 2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 2008;111:1044-1053.
12. Kaplan E, Meier P, Kaplan E, et al. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Greenwood M. The natural duration of cancer. Report on public health and medical subjects, London, England: His Majesty's Stationery Office; 1926;33:1-26.
14. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley; 1980.
15. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
16. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP 309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007;13:4123-4129.
17. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP 309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-288.
18. Asomaning K, Reid AE, ZhouW, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res 2008;14:4010-4015.
19. Ohmiya N,Taguchi A,Mabuchi N, et al.MDM2promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-4440.
20. Lind H, Zienolddiny S, Ekstrøm PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;119:718-721. (Pubitemid 43955729)
21. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-117.
22. Cattelani S, Defferrari R, Marsilio S, et al. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: Results of a pilot study on 239 patients. Clin Cancer Res 2008;14:3248-3253.
23. Bond GL, Hirshfield KM, Kirchhoff T, et al.MDM2SNP 309 accelerates tumor formation in a gender-specific and hormone dependent manner. Cancer Res 2006;66:5104-5110.
24. Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP 309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009;33:1454-1458.
25. Han JY, Lee GK, Jang DH, et al. Association of p53 codon 72 polymorphism and MDM2 SNP 309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807.
26. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007;25:2243-2247. (Pubitemid 46954650)
27. Tu HF, Chen HW, Kao SY, et al. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol 2008;87:243-252.